Score Overview
Explore the 2021 public Archive ranking →
Where Charles River Laboratories has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- CRL
2011: 57.2% · 2021: 7.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 295.96 | — |
1 Year2025-09-29 | $ 146.99 | 101.35% |
5 Years2021-09-29 | $ 423.09 | -30.05% |
10 Years2016-09-29 | $ 82.54 | 258.57% |
20 Years2006-09-29 | $ 43.41 | 6x |
All Time2000-06-23 | $ 22.00 | 13x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2000-06-23 |
|---|---|---|---|---|---|---|
| Price | $ 295.96 | $ 146.99 | $ 423.09 | $ 82.54 | $ 43.41 | $ 22.00 |
| Return | — | 101.35% | -30.05% | 258.57% | 6x | 13x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3.99B | -$ 238M | $ 192M |
| 2025 | $ 4.01B | -$ 144M | $ 213M |
| 2024 | $ 4.04B | $ 10M | $ 194M |
| 2023 | $ 4.12B | $ 474M | $ 276M |
| 2022 | $ 3.97B | $ 486M | $ 233M |
| 2021 | $ 3.54B | $ 390M | $ 246M |
| 2020 | $ 2.92B | $ 364M | $ 229M |
| 2019 | $ 2.62B | $ 252M | $ 238M |
| 2018 | $ 2.26B | $ 226M | $ 195M |
| 2017 | $ 1.85B | $ 123M | $ 163M |
| 2016 | $ 1.68B | $ 154M | $ 117M |
| 2015 | $ 1.36B | $ 149M | $ 117M |
| 2014 | $ 1.29B | $ 126M | $ 160M |
| 2013 | $ 1.16B | $ 102M | $ 155M |
| 2012 | $ 1.12B | $ 97M | $ 109M |
| 2011 | $ 1.14B | $ 109M | $ 68M |
| 2010 | $ 1.13B | -$ 336M | $ 188M |
| 2009 | $ 1.20B | $ 114M | $ 182M |
| 2008 | $ 1.34B | -$ 521M | $ 243M |
| 2007 | $ 1.23B | $ 154M | $ 240M |
| 2006 | $ 1.05B | -$ 55M | $ 182M |
| 2005 | $ 1.12B | $ 141M | $ 116M |
| 2004 | $ 766M | $ 89M | $ 207M |
| 2003 | $ 613M | $ 80M | $ 195M |
| 2002 | $ 554M | $ 50M | $ 122M |
| 2001 | $ 465M | $ 35M | $ 58M |
| IPO2000 | $ 306M | -$ 11M | $ 33M |
Charles River Laboratories fundamental performance
Between 2015 and 2025, revenue grew from $ 1.36B to $ 4.01B and net income went from $ 149M to -$ 144M. Revenue increased in 7 of those 10 years; net income in 5.
Across Charles River Laboratories's full reported history, from 2000 to 2025, revenue grew from $ 306M to $ 4.01B and net income went from -$ 11M to -$ 144M. Revenue increased in 73% of the years measured; net income in 65%.
Charles River Laboratories currently holds a 20-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Membership
Continue CRL’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
